ATN 015: SHORT-CYCLE THERAPY IN ADOLESCENTS WITH ESTABLISHED VIRAL SUPPRESSION

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 这项II期HIV AIDS研究旨在获得关于青少年短周期治疗（SCT）概念的初步安全性数据。本研究的主要目的是检验安全性假设，即与接受持续高剂量抗逆转录病毒治疗（HAART）的受试者相比，接受SCT的受试者中病毒载量反弹不会增加。作为一项II期研究，其目的是在现有生物行为数据严格定义的少数受试者中有效和精确地证明SCT的安全性和初步疗效。本研究的主要目的是比较病毒载量抑制（将评估病毒载量反弹时1，000拷贝/ml）。比较期为从研究入组至研究管理结束（24周）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This Phase II HIV AIDS study is designed to obtain preliminary safety data on the concept of short cycle therapy (SCT) in adolescents. The primary objective of this study is to test the safety hypothesis that viral load rebound will not be increased in subjects on SCT compared to subjects on continuous highly antiretroviral therapy (HAART). As a Phase II study, its objective is to demonstrate with efficiency and precision the safety and preliminary efficacy of SCT in a small number of subjects tightly-defined by existing bio-behavioral data. The main aim of this study is to compare viral load suppression ( 1,000 copies/ml at time of viral load rebound will be assessed. The comparison period will be from study entry to administrative end of the study (24 weeks).